PHENYLephrine in 0.9 sodium chloride, 400 mcg /10 mL, (40 mcg/mL), 10 mL Syringe, Rx only, CAPS, ...
FDA Drug Recall #D-1078-2023 — Class II — July 17, 2023
Recall Summary
| Recall Number | D-1078-2023 |
| Classification | Class II — Moderate risk |
| Date Initiated | July 17, 2023 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Central Admixture Pharmacy Services Inc |
| Location | San Diego, CA |
| Product Type | Drugs |
| Quantity | 16,971 syringes |
Product Description
PHENYLephrine in 0.9 sodium chloride, 400 mcg /10 mL, (40 mcg/mL), 10 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6007-1
Reason for Recall
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot: 17-270510, 17-270512, Exp. 7/16/2023; 17-270665, 17-270699, Exp. 7/18/2023; 17-270812, Exp. 7/19/2023; 17-271062, 17-271063, 17-271064, 17-271065, Exp. 7/24/2023; 17-271350, 17-271357, 17-271421, 17-271422, Exp. 7/30/2023; 17-271836, 17-271848, Exp. 8/6/2023; 17-271890, Exp. 8/7/2023; 17-271943, 17-271954, 17-271958, 17-271962, Exp. 8/8/2023; 17-272162, 17-272174, 17-272175, 17-272176, 17-272177, Exp. 8/13/2023; 17-272444, 17-272456, 17-272473, Exp. 8/16/2023; 17-272717, 17-272721, 17-272732, Exp. 8/21/2023; 17-273550, 17-273565, 17-273579, 17-273580, Exp. 9/5/2023.
Other Recalls from Central Admixture Pharmacy Services Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0019-2024 | Class II | fentaNYL, 100 mcg/2 mL, (50 mcg/mL), 3 mL Syrin... | Sep 21, 2023 |
| D-0023-2024 | Class II | fentaNYL, 5,000 mcg/100 mL, (50 mcg/mL), 100 mL... | Sep 21, 2023 |
| D-0027-2024 | Class II | HYDROmorphone in 0.9% sodium chloride, 6 mg/30 ... | Sep 21, 2023 |
| D-0017-2024 | Class II | fentaNYL 2 mcg/mL and bupivacaine 0.125% PF in ... | Sep 21, 2023 |
| D-0030-2024 | Class II | HYDROmorphone in dextrose 5%, 3 mg/30 mL, (0.1 ... | Sep 21, 2023 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.